Aquamid and Permanent Dermal Fillers: What Practitioners Should Understand

Most dermal fillers used today are biodegradable, but a small category of permanent and semi-permanent products remains part of the wider filler landscape, and Aquamid is among the longest-standing examples. Understanding how permanent fillers differ from HA-based products — in composition, regulatory positioning and patient selection — is useful even for practitioners who work exclusively with resorbable materials.

What Aquamid Is

Aquamid was first approved for use in Europe in 2001. It is composed of roughly 97.5 percent water and 2.5 percent polyacrylamide, forming a clear, non-absorbable gel implant rather than a resorbable HA-based product.

Permanent, Semi-Permanent and Non-Permanent: A Useful Framework

Dermal fillers are broadly grouped by how the body handles them over time:

• Non-permanent products are absorbed over roughly a month to a year and carry the broadest range of approved uses. Most HA fillers fall into this category.
• Semi-permanent products are absorbed over a longer horizon, roughly two years, and are typically approved for a narrower set of uses such as lipoatrophy correction and volume or contour work.
• Permanent products are not absorbed at all and have historically been reserved for specific reconstructive indications, such as correcting volume loss from illness or trauma, rather than routine cosmetic use.

Why Permanence Changes the Risk Calculus

Because a permanent implant is not naturally cleared and cannot be reversed the way HA is, patient selection, technique and long-term monitoring carry considerably more weight than with resorbable products. Any complication or tissue change that emerges years after treatment must be managed without the safety net of enzymatic reversal, which is a materially different risk profile from products designed to metabolise on their own. This is also why many regulatory frameworks treat permanent fillers as a distinct product class from resorbable ones, often with additional training, consent or classification requirements attached.

What the Published Data Show

Early clinical experience with Aquamid, including cohort studies numbering in the hundreds of patients, reported that a majority were satisfied with their results, while a minority experienced adverse effects — a profile broadly consistent with what would be expected of any subcutaneous implant material assessed over the long term. As with any permanent material, the relevant safety question is less about the initial result and more about tissue behaviour over years rather than months.

Where Permanent Fillers Fit Today

Most routine volumising work has moved toward HA and biostimulatory products, largely because of their reversibility and more flexible risk profile. Permanent fillers such as Aquamid now tend to occupy a narrower, more specialist niche, generally reserved for cases of genuine reconstructive need where long-term correction is prioritised over adjustability. Practitioners who do not routinely work with permanent materials still benefit from understanding this category, if only to recognise it correctly when a patient presents having had a permanent filler placed years earlier by another provider.

The Takeaway

Permanent fillers such as Aquamid illustrate, by contrast, why reversibility became such a valued property in modern filler formulations. Patient selection and informed consent carry particular weight whenever a non-resorbable product is being considered, given the absence of a straightforward correction pathway.

To compare Aquamid with resorbable alternatives, browse the dermal fillers catalogue.